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Haemoglobinopathies are considered the most 
common monogenic disorders. Clinically significant 
conditions are caused primarily by mutations in 
either the β- or α-globin genes. Mutations that 
cause quantitative deficiencies in β-globin result in 
β-thalassaemia, while qualitative variants result in β-globin variants, 
such as sickle cell anaemia. These are all inherited in an autosomal 
recessive manner. There are four α-globin genes in the genome; 
thus mutations can occur in one, two, three or four genes, resulting 
in increasing severity of α-thalassaemia, and a more complex 
inheritance pattern.[1,2]
Haemoglobinopathies are common mainly as a result of 
heterozygotes having a selective advantage against malaria. Their 
geographical distribution is thus generally in tropical and sub-
tropical areas of the world, where malaria is/was previously endemic. 
With population migration, however, haemoglobinopathies are 
encountered in significant frequencies in many countries globally, 
particularly those with large migrations from Africa, the Middle East, 
the Indian subcontinent, South-East Asia, and the Mediterranean. 
Haemoglobinopathies thus represent a significant and increasing 
health burden in many parts of the world.[3]
While seasonal transmission of malaria has occurred in South 
Africa (SA), particularly in the north, the country is mostly situated 
out of the malaria belt. However, there have been a number of earlier 
and more recent migrations of groups of people into the area, with 
their respective haemoglobinopathies. The south-eastern Bantu 
migrated into southern Africa some 2 000 years ago and have high 
frequencies of the -α3.7 chromosome, suggesting it may be the oldest 
malaria protective trait in Africa.[4] From the early 1860s until 1911, 
thousands of Indians were recruited to work on farms in Natal 
under the indentured labour system. They were accompanied by 
immigrants seeking opportunities as traders or craftsmen.[5] More 
recently, families from the Mediterranean, north Africa, Asia and the 
African subcontinent have moved to SA. Thus, haemoglobinopathies 
are seen in diverse populations in SA, broadly reflecting their origins. 
Further, the globin genes were among the first human genes cloned 
in the recombinant DNA era and they served as model genes for the 
establishment of genetic services worldwide, with the first molecular 
prenatal diagnosis being offered in 1978 for sickle cell anaemia.[6] In SA, 
the first molecular genetics services for diagnostic testing and prenatal 
diagnosis were also set up for haemoglobinopathies, in the early 1980s, 
with the foresight and guidance of Professor Trefor Jenkins. The first 
prenatal diagnosis in SA was performed for an Indian couple at risk for 
sickle cell anaemia.[7] Shortly thereafter, the first chorionic villus biopsy 
was performed in SA for an Indian couple at risk for β-thalassaemia.[8] 
The laboratory in Johannesburg has continued to develop and expand 
its molecular diagnostic service for haemoglobinopathies, initially using 
Southern blotting and linked marker analysis, converting to polymerase 
chain reaction (PCR)-based mutation detection, with allele-specific 
oligonucleotides and amplification refractory mutation system (ARMS). 
Later a multiplex PCR (mPCR) system for α-thalassaemias and gene 
sequencing and multiplex ligation probe amplification (MLPA) for 
β-globin gene cluster analysis was introduced.
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Background. Haemoglobinopathies are seen mostly in regions where malaria occurs or has occurred, but population migration has resulted 
in affected individuals being identified in many countries globally. The first molecular genetics services for diagnostic testing and prenatal 
diagnosis were established, both worldwide and in South Africa (SA), for haemoglobinopathies. 
Objective. To analyse the diagnostic service offered by the Division of Human Genetics, National Health Laboratory Service and University 
of the Witwatersrand, from 1983 to 2012.
Methods. A retrospective file analysis (N=1 249) was performed for all individuals who had molecular genetic testing for α-thalassaemia, 
β-thalassaemia and sickle cell anaemia to examine indications for testing, population origins of patients and molecular genetics findings.
Results. The α-thalassaemia testing was requested predominantly to explain microcytic hypochromic haematological indices. Five α-globin 
deletions were identified, the most common being the -α3.7, in individuals of different ethnicities. For β-thalassaemia and sickle cell anaemia, 
most testing was performed for prenatal diagnosis purposes. For sickle cell anaemia, most prenatal tests were requested by African families. 
The β-thalassaemia families were mostly of Indian or Mediterranean origin. The most common mutation identified in all Indian groups 
was IVS1 nt5 (G>C) (c.92+5G>C) and in individuals from the Mediterranean, IVS1 nt110 (G>A) (c.93-21G>A).
Conclusion. The molecular genetics service for haemoglobinopathies in SA is comprehensive and specific to the needs of local ethnic groups. 
Clinically significant haemoglobinopathies occur at significant frequencies in specific high-risk ethnic groups. Appropriate screening 
programmes should be initiated so that genetic counselling and reproductive options can be offered. 
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profiles of patients and molecular genetics findings. The DHG was 
initially part of the South African Institute for Medical Research, but 
now falls within the National Health Laboratory Service (NHLS).
Methods
The data collected from molecular genetics files were analysed for all 
patients referred for haemoglobinopathy testing to the DHG (N=1 249). 
These patients came from 465 families. Files are allocated a sequential 
family number, which incorporates a code defining whether they were 
referred for α-thalassaemia, β-thalassaemia or sickle cell anaemia 
testing. There are some redundancies and anomalies in the system as 
families are usually given two codes if the original test request includes 
more than one haemoglobinopathy. In addition, they may occasionally 
have a diagnosis different from the original referral. Family members 
(including spouses) are all linked under the same alpha-numeric code. 
Files were available dating back to 1983 for α-thalassaemia, 1984 
for β-thalassaemia and 1987 for sickle cell anaemia. Only files with 
molecular genetic data were included in the analysis. If no such data 
were available, or if samples were not analysed, files were excluded. All 
files until 31 December 2012 were included.
The characteristics of the sample, and the indications for testing 
were assessed, as well as the molecular genetic findings. 
Results
α-thalassaemia
Altogether, 292 individuals were tested for α-thalassaemia, including 
256 unrelated individuals from 241 families. The majority of referrals 
to the molecular diagnostic laboratory were tested as single individuals, 
with the most common indication for testing being unexplained 
microcytic hypochromic indices on full blood count (FBC) analysis. 
Individuals were initially investigated for common α-globin deletions 
by the Southern blotting technique. An mPCR assay[9] was introduced 
in 2001, which detects six common deletions in one assay. 
Five common α-globin deletions were identified with 10 genotypes 
in 132/256 (51.6%) unrelated individuals tested (Table 1). The most 
common deletion identified was the -α3.7 in individuals from many 
different ethnic groups. In a further 124 individuals (48.4%), no 
mutation was found. Despite the request form asking for haematological 
results (FBC, haemoglobin (Hb) electrophoresis, iron studies) so that 
haematological and genetic results could be correlated, some or all of 
this information was only available for 193/292 (66%) individuals. In 
129/193 (67%) individuals, the haematological results were broadly 
consistent with the genetic results, either because an α-thalassaemia 
mutation was identified (n=100) or a different genetic mutation was 
ultimately identified (n=29). In the remaining 64/193, genetic and 
haematology results were inconsistent. No α-thalassaemia mutations 
were identified, but 53 individuals had microcytic hypochromic indices. 
However, for many, the haematological results were incomplete, so a 
full assessment was not possible. 
There were three families in which a proband, with features 
suggestive of haemoglobin H (HbH) disease, was tested. Deletions 
of three α genes were identified in two of these families. In the third 
family, a -(α)20.5 deletion was identified, but not a second mutation 
(Table 1). In one of these families, the proband was an adult female 
of Mediterranean origin concerned about her children’s risks of a 
significant haemoglobinopathy. 
Only four prenatal tests were performed for α-thalassaemia, two for 
a Chinese family, where both parents were carriers of a --SEA mutation 
and they had three previous stillborn infants with hydrops fetalis. One 
fetus was found to be a carrier, the other unaffected. The other two 
prenatal tests were inappropriate requests. In the first, fetal testing 
for α-thalassaemia was requested on an amniotic fluid sample. The 
father was confirmed to be an α-thalassaemia carrier, but the mother 
was shown to be a β-thalassaemia carrier after the amniocentesis had 
been performed. The second fetus, referred because of the presence of 
hydrops fetalis, was subsequently shown to have trisomy 21.
In a consanguineous Indian Muslim family, two children had HbH 
disease. No deletions could be demonstrated. The parents shared 
a haplotype across the entire α-globin cluster and it was proposed 
that the children who were homozygous for the haplotype were 
homozygous for an α2 point mutation.[10] 
There were four other families with possible non-deletion α 
variants not identified with current testing. These were not pursued 
at the time because of cost and technical constraints, and the small 
number of patients for whom such testing would be indicated. 
Sickle cell anaemia
Samples for a total of 319 individuals from 126 families were analysed 
for the sickle cell (βS) mutation, only one with known consanguinity. 
Of the 126 families, 116 were of African origin, four Indian, one mixed 
ancestry and five unknown. The 116 African families originated from 
at least 14 African countries in sub-Saharan Africa, and included 30 
from the Democratic Republic of Congo, 16 from Angola, 10 from 
Nigeria and five from Zimbabwe. None originated from SA. It could 
not be determined whether the African patients were resident in SA 
or had only come to the country for their diagnostic procedures. 
Altogether, 175 carrier tests and 31 clinical diagnostic tests were 
performed, many on parents of affected individuals as part of a 
workup for prenatal diagnosis. In 24 families, carrier screening was 
performed premaritally or at the time of other pregnancy testing 
(e.g. amniocentesis for advanced maternal age). In four families, 
confirmation of the clinical diagnosis was requested, where some of 
the clinical features were not entirely consistent with homozygosity 
for sickle cell anaemia. A single preclinical diagnosis was performed 
on a 6-month-old sibling of an affected individual. 
There were 110 prenatal tests performed for 75 families, with 55 
families having one prenatal test, 12 having two, four having three, two 
Table 1. α-thalassaemia genotypes and population origins of 
individuals tested (N=256)
Genotype
Unrelated 
individuals 
(N=256), n Population groups 
-α20.5/? 1 Mediterranean*
-α3.7/--MED 1 Mediterranean*
-α3.7/--SEA 1 Asian†
-α3.7/-α3.7 52 Black, Indian,‡ mixed ancestry
-α3.7/-α4.2 3 Arab, Indian‡
-α4.2/-α4.2 3 Indian,‡ mixed ancestry, unknown
-3.7/αα 57 Arab, black, Indian,‡ Mediterranean,* 
mixed ancestry, white§
--SEA/αα 6 Asian†
--4.2/αα 5 Indian,‡ unknown
--MED/αα 3 Mediterranean,* white,† unknown
αα/αα 124¶ Arab, Asian,† black, Indian‡ 
Mediterranean,* mixed ancestry, white†
*Mediterranean includes Greek and Italian groups.†Asian includes Chinese, Filipino and Indonesian groups.‡Indian includes Muslim and Hindu groups.§White includes Afrikaans, Jewish and Yugoslavian groups.¶Includes individuals with possible non-deletion mutations (n=5).
MOLECULAR GENETICS
991  December 2013, Vol. 103, No. 12 (Suppl 1)  SAMJ
families having four and one each having five and six tests, respectively. 
The 110 prenatal tests were performed on 58 amniotic fluid samples, 
49 chorionic villus samples and three cordocenteses. The numbers, 
although fluctuating, have generally increased over the years, so that 
sickle cell anaemia is currently the most common indication for prenatal 
diagnosis by DNA testing in the laboratory (Fig. 1). The numbers of 
unaffected (n=29), carrier (n=59), affected (n=22) and no result (n=1) 
fetuses did not differ from what would be expected based on Mendelian 
ratios. One erroneous report is known, where an affected fetus was 
misdiagnosed as a heterozygote, due to maternal tissue contamination 
of the specimen. Since then, from the year 2000, all heterozygous 
specimens have been checked routinely for maternal contamination. In 
16 families a prenatal workup was requested but no prenatal test had yet 
been performed (including one family with non-paternity). 
In addition, six fetuses were shown to have trisomies on routine 
karyotyping performed at the time of prenatal diagnosis; five had 
trisomy 21 and one trisomy 18, three being in mothers of advanced 
maternal age.
Three unusual probands were tested. In one, the proband was a 
heterozygote for the βS mutation. Clinically, she had features suggestive 
of homozygosity for sickle cell anaemia, with many sickling crises. No 
cis- or trans-variation in her β-globin genes could be identified. She 
was subsequently shown to have pyruvate kinase deficiency (Dr N Alli, 
personal communication). A second heterozygous proband also had 
clinical features of pseudoxanthoma elasticum and a third appeared to 
have a co-inherited non-deletion α-globin variant. 
β-thalassaemia
A total of 416 individuals from 134 families were tested for 
β-thalassaemia. The majority of people (324 individuals from 84 
families) were tested as part of a workup for prenatal diagnosis, where 
there was a previously affected child (70 families) or both parents had 
been identified as carriers haematologically (14 families). At least eight 
of these families were known to be consanguineous. For most of the 
families, however, information on consanguinity was not provided. The 
majority of families were from the two known high-risk population 
groups for β-thalassaemia in SA, namely individuals from the Indian 
subcontinent (62 families, of whom 39 were Muslim and 23 were 
Hindu) and individuals from Mediterranean countries (18 families). 
Three families were of mixed ancestry and one of unknown ethnicity. 
In the majority of families, both parents were β-thalassaemia carriers, 
so they were at risk of having children with thalassaemia major. There 
were also 13 βS/β-thalassaemia families included in the analysis (seven 
Indian, two Mediterranean, three African and one of mixed ancestry).
There were 59 prenatal tests performed for 43 families (including 
two βS/β-thalassaemia families), with 29 families having one test, 12 
having two and two having three. Mendelian ratios of fetuses were 
as expected (14 unaffected, 27 heterozygotes, 12 affected). In six 
tests performed early on, full testing was not available, as either only 
one parental mutation was identified and/or linked markers were 
uninformative for one parent. Four fetuses were therefore considered 
at increased risk of a haemoglobinopathy, while two were at reduced 
risk. No errors were reported. 
No trisomies were documented from the data available. 
Chromosome results were not available on all fetuses. The numbers 
of prenatal test requests have remained relatively constant over 
the last 25 years with 2 - 3 requests per year (Fig. 1). Recently, two 
families have opted for pre-implantation genetic diagnosis. One has a 
healthy baby as a result. The other couple is currently going through 
the process. They would like to select an embryo for implantation, 
which is both unaffected for β-thalassaemia and a human leukocyte 
antigen (HLA) match for their affected child, so that the infant could 
be a suitable marrow donor for their affected child.
In 50 individuals, mutation screening was requested to clarify 
haematological findings. In 14 of these, both α- and β-thalassaemia 
testing were requested. As with α-thalassaemia testing requests, 
in many cases haematological findings were not provided for 
interpretation and correlation. In 15/50 individuals a β-thalassaemia 
mutation was identified. Four of these individuals were of Indian 
ancestry, four of mixed ancestry, five of Mediterranean and two of 
unknown ancestry. 
The mutation profiles differed, based on the ethnic origins of the 
patients. Both the old nomenclature and the new Human Genome 
Variation Society (HGVS) nomenclature[11] are used in Tables 2 and 3, 
but only the old nomenclature is used in the text for simplicity. Mutations 
identified in the Indian families (broadly divided into the two major 
religious groups) are shown in Table 2. The most common mutation 
identified in both Indian groups was IVS1 nt5 (G>C). In the Muslim 
group, two other mutations (IVS1  nt1  (G>T) and 619  bp deletion) 
together accounted for an additional 36% of mutations identified. 
These two mutations are predominantly found in individuals from the 
Memon subgroup. In the Hindus, the codon 41 - 42 (-TTCT) mutation 
accounted for an additional 12.5% of mutations. The mutations found 
in the families of Mediterranean ancestry are shown in Table 3. The 
most common mutation (77%) is the IVS1 nt110 (G>A).
Interestingly all three mixed-ancestry families had at least one 
suspected deletion mutation. A haemoglobin E (HbE) mutation was 
identified in one family, and a codon 30 (G>C) mutation in another. 
In the proband heterozygous for the codon  30  (G>C) mutation, a 
deletion was confirmed with MLPA analysis (P102-B2  HBB probe 
mix)[12] and extends from exon 3 of the δ-globin gene to intron 2 of the 
β-globin gene. The flanking probes, exon 1 of the δ-globin gene and 
exon 3 of the β-globin gene were not deleted. The other two patients 
have not been screened.
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Fig. 1. β-thalassaemia (BTH) and sickle cell anaemia (sickle haemo-
globinopathy (SHB)) prenatal tests performed over 5-year periods from 
1988 to 2012.
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Discussion
Many different globin gene mutations have 
been identified through the diagnostic 
service of the DHG. They broadly reflect 
the population origins of the individuals 
represented. The laboratory has established 
a reputation for offering a comprehensive 
genetic service and thus both routine and 
atypical cases are referred.
α-thalassaemia 
Our results emphasise the high frequency of 
α-thalassaemia mutations in many populations 
in SA. The distribution of the α-thalassaemia 
mutations reflects the population origins 
of the individuals, similar to the situation 
worldwide. [1] The majority of mutations are 
single α-gene deletions in heterozygous 
(-α3.7/αα or -α4.2/αα), homozygous (-α3.7/-α3.7 
or -α4.2/-α4.2) or compound heterozygous 
(-α3.7/-α4.2) forms. Only a small number of 
individuals with both α-genes deleted in cis (--/
αα) were identified. Thus, not unexpectedly, 
only a few patients with HbH disease or 
hydrops fetalis have been documented in 
SA. Nevertheless, one of the first prenatal 
diagnoses for a haemoglobinopathy was 
performed for a couple of Chinese ancestry, 
where both parents carried a --SEA mutation. 
A sizeable Chinese population of ~250  000 
- 300  000 exists in Johannesburg.[13] With an 
expected birth rate for Hb Bart’s hydrops fetalis 
of 0.5 - 5/1 000 births and for HbH disease of 
4 - 20/1 000 in the Chinese population,[1] it is 
uncertain why there are so few referrals. 
The majority of α-thalassaemia referrals 
were single individuals for the purpose of 
α-thalassaemia mutation detection. This 
usually stemmed from an inability to identify 
an explanation for microcytic hypochromic 
indices on FBC analysis with normal iron 
levels. Although these haemoglobinopathies 
do not cause clinically significant diseases, 
they cause concern for medical practitioners. 
DNA testing has proven to be helpful in 
confirming the presence of α-thalassaemia 
mutations definitively, so that individuals are 
given appropriate management advice. 
It is difficult to comment on the detection 
rate of the α-thalassaemia multiplex assay 
as the indications for testing are often 
not provided, or only partial information 
is available. As a significant number 
of individuals are identified without any 
detectable α-thalassaemia deletions, the 
possibility exists that non-deletion or rare 
deletion variants are being missed. However, 
the likelihood that these individuals are non-
α-thalassaemia patients is more probable. 
Only a few individuals were identified who 
are likely to have α-globin mutations, but 
whose mutations remain unidentified. 
Further, despite the request form asking for 
an FBC and Hb electrophoresis result to be 
provided, this did not occur in ~40% of cases. 
In many, only partial information is provided. 
Thus it is difficult to assess the correlation 
between haematological and genetic findings. 
In addition, the haematological workup in 
itself is also inadequate in a number of cases. 
In many laboratories a qualitative assay is being 
used to quantitate HbA2 levels. Accurate HbA2 
levels are important to distinguish α- from 
β-thalassaemia. These difficulties are reflected 
in the thalassaemia testing request, where 
in a notable number of cases, both α- and 
β-thalassaemia testing are requested, despite the 
fact that the majority should be distinguished 
haematologically. In many cases a non-genetic 
explanation for the haematological findings 
has not been completely excluded.
Table 2. β-thalassaemia mutations identified in unrelated individuals of 
Indian ancestry
Mutations (nomenclature) Muslim patients 
(N=78), n (%)
Hindu patients 
(N=48), n (%)Old HGVS[11]
IVS1 nt5 (G>C) c.92+5G>C 32 (41) 28 (58.3)
IVS1 nt1 (G>T) c.92+1G>T 18 (23.1) 0 (0)
619 bp deletion 619 bp deletion 10 (12.8) 1 (2.1)
Codon 41 - 42 (-TTCT) c.124_127delTTCT 1 (1.3) 6 (12.5)
Codon 8 - 9 (+G) c.27_28insG 3 (3.8) 0 (0)
Codon 5 (-CT) c.17_18delCT 2 (2.6) 0 (0)
Codon 15 (G>A) c.47G>A 2 (2.6) 3 (6.3)
HbE c.79G>A 1 (1.3) 3 (6.3)
Codon 44 (-C) c.135delC 1 (1.3) 0 (0)
Codon 30 (G>A) c.92G>A 1 (1.3) 0 (0)
Codon 30 (G>C) c.92G>C 1 (1.3) 1 (2.1)
CAP +1 (A>C) c.-50A>C 1 (1.3) 0 (0)
IVS1 nt2 (T>A) c.92+2T>A 0 (0) 1 (2.1)
-28 (A>G) c.-78A>G 0 (0) 1 (2.1)
Poly A (T>C) c.*+110T>C 0 (0) 1 (2.1)
HbD Punjab c.364G>C 1 (1.3) 0 (0)
Large deletion* N/A 2 (2.6) 0 (0)
Unknown† N/A 2 (2.6) 3 (6.3)
HGVS = Human Genome Variation Society; MLPA = multiplex ligation probe amplification; N/A = not applicable.
* MLPA analysis shows that the deletion includes the ψ, β, δ and β genes. The 3’ extent of the deletion is unknown as the 
probes used only extend to 9 kb downstream of the β gene. †Gene not sequenced in 3 patients.
Table 3. β-thalassaemia mutations identified in unrelated individuals of 
Mediterranean ancestry
Mutations (nomenclature)
Mediterranean patients (N=35), n (%)Old HGVS[11]
IVS1 nt110 (G>A) c.93-21G>A 27 (77.1)
Codon 39 (C>T) c.118C>T 1 (2.9)
IVS1 nt1 (G>A) c.92+1G>A 1 (2.9)
IVS1 nt6 (T>C) c.92+6T>C 2 (5.7)
IVS2 nt1 (G>A) c.315+1G>A 1 (2.9)
IVS2 nt745 (C>G) c.316-106C>G 1 (2.9)
Large deletion* N/A 1 (2.9)
Unknown† N/A 1 (2.9)
HGVS = Human Genome Variation Society; MLPA = multiplex ligation probe amplification;  
ARMS = amplification refractory mutation system; N/A = not applicable.
* MLPA analysis shows a deletion including exon 3 of the δ gene (but excluding exon 1 of the δ gene), the entire β gene, and 
extending 0.8 kb downstream of the β gene. † Tested early on for common mutations by ARMS with no mutation identified and sequencing not performed.
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Sickle cell anaemia
Sickle cell anaemia is the most common severe haemoglobinopathy 
in Africa, with high carrier rates in the tropical regions.[14] It is thus 
not surprising that the majority of patients referred to the DHG have 
origins in central Africa. Our records did not allow us to analyse 
how many patients only came to SA for prenatal testing, but are 
resident elsewhere in Africa and how many are resident locally, but, 
anecdotally, both scenarios do occur. The βS mutation does occur at a 
low frequency in the northern parts of SA,[15] but none of the families 
with an affected proband in this study were from SA. 
The βS mutation also occurs in India, and the carrier frequency 
is similar to that for β-thalassaemia in the SA Indian population. [10] 
However, far fewer patients or families are seen with sickle cell 
anaemia, possibly because the patients are clinically mild and do not 
present with severe symptoms. Compound heterozygotes for βS and 
β-thalassaemia mutations are diagnosed, and these are included in 
the β-thalassaemia analysis. 
The majority of sickle cell anaemia tests are performed for families 
as part of a prenatal diagnostic workup. Sickle cell anaemia is the 
most common indication for prenatal diagnosis in the DHG, and the 
number of prenatal tests performed annually appears to be increasing. 
Although some carrier testing for the βS mutation was performed 
by DNA analysis, this should not be performed routinely and is 
generally inappropriate. Qualitative Hb analysis remains the method 
of choice and is cheaper. In rare cases, molecular analysis may assist 
in resolving a complex case. 
β-thalassaemia
As would be expected, β-thalassaemia testing was mostly performed for 
prenatal diagnosis purposes for families who were known to be at risk 
of a severe haemoglobinopathy. Early on, linked marker analysis was 
used, but this has gradually been replaced almost entirely by mutation 
analysis. MLPA has recently been introduced to identify large deletions 
in the β-globin gene cluster. Early on in the provision of the service, 
couples were sometimes only semi-informative with linked markers, 
thus only allowing for modification of fetal risk, based on information 
from the informative parent. Few unidentified mutations remain in 
verified β-thalassaemia families; thus almost all prenatal tests are offered 
with direct mutation analysis and high certainty. Carrier tests requested 
based on abnormal haematological findings and premarital screening of 
couples were less frequent indications for β-globin gene analysis. 
The number of prenatal tests performed for β-thalassaemia has 
remained constant at 2 - 3 per year. Most couples were at risk for a 
child with β-thalassaemia, but some were at risk for βS/β-thalassaemia. 
The population specificity of β-thalassaemia mutations has been 
well documented in many populations. In most populations, a small 
number of mutations account for the majority of gene abnormalities 
in each group.[16] In the Muslim group, three mutations account for 
77% of mutations, and in the Hindu group, two mutations account 
for 71%. In the Mediterranean group, one mutation accounts for 71%. 
Not only do populations’ mutation spectra differ based on their 
geographical origins, but in addition, due to migrations of small groups 
of individuals and local founder effects, the mutation spectra may 
differ somewhat in people of similar origin. This is demonstrated in 
both of the SA high-risk populations – the Indian and Mediterranean 
groups. In the Indians, the most common mutation is the same in 
both the Muslim and Hindu groups. However, the 619  bp deletion 
and the IVS1 nt1 (G>T) mutation, which together account for 36% 
of mutations in the Muslims, are occasionally seen in Hindu people. 
Further, they appear at particularly high frequency in the Muslim 
Memon subgroup. Similarly the codon  41  -  42  (-TTCT) mutation, 
which accounts for 12% of mutations in the Hindu population, is 
only seen rarely in Muslims. In the early testing strategy, population 
identification was critically important as targeted mutation analysis 
was performed. However, as sequencing has become easier and 
less costly, this approach is no longer cost-effective and in most 
cases mutation identification is now achieved through sequencing. 
Targeted tests are, however, useful for prenatal testing. 
Conclusion
The molecular genetics service offered to individuals in SA with 
haemoglobinopathies has improved technically and a wide knowledge 
base has developed over time, so that a comprehensive service 
specific to the needs of the local population is provided. Genetic 
testing is helpful to confirm diagnoses, particularly when they are 
complex, and for carrier testing and prenatal diagnosis. Prenatal 
diagnosis remains the most common indication for testing. 
Comprehensive haematological assessment of patients should 
be performed prior to genetic analysis. These results, together with 
the ethnic group of the patient and information on consanguinity, 
should be passed on to the laboratory to ensure optimal testing 
and interpretation of the genetic data. This would prevent over-
investigation and result in the best possible management of 
individuals with haemoglobinopathies. 
Although clinically significant haemoglobinopathies are not the 
most common monogenic disorders in SA, they do occur at significant 
frequencies in high-risk minority ethnic groups. Their treatment is 
expensive and will impact on health budgets, particularly if immigration 
from high-risk geographical areas increases. Further, with integration 
into the local communities, it will be increasingly difficult to direct 
testing at high-risk groups. It is important that appropriate screening 
programmes are initiated, so that high-risk couples are identified and 
appropriate genetic counselling and reproductive options are offered. 
Acknowledgments. The authors acknowledge the clinicians and counsellors 
who referred these patients to the DHG, and the staff members of the 
Molecular Genetics Laboratory who have performed many tests over the 
years. 
References
1. Galanello R, Cao A. Alphα-Thalassaemia. In: Pagon RA, Adam MP, Bird TD, et al, eds. GeneReviews. 
Seattle: University of Washington, 1993-2013. http://www.ncbi.nlm.nih.gov/books/NBK1435/ 
(accessed 11 October 2013).
2. Cao A, Galanello R, Origa R. Betα-thalassaemia In: Pagon RA, Adam MP, Bird TD, et al, eds. 
GeneReviews. Seattle: University of Washington, 1993-2013. http://www.ncbi.nlm.nih.gov/books/
NBK1426/ (accessed 11 October 2013).
3. Weatherall DJ. Hemoglobinopathies worldwide: Present and future. Curr Molec Med 2008;8(7):592-
599. [http://dx.doi.org/10.2174/156652408786241375]
4. Ramsay M, Jenkins T. α-thalassaemia in Africa: The oldest malaria protective trait? Lancet 
1984;324(8399):410. [http://dx.doi.org/10.1016/S0140-6736(84)90581-6]
5. Bhana S, Brain JB. Setting Down Roots: Indian Migrants in South Africa, 1860-1911. Johannesburg: 
Witwatersrand University Press, 1990.
6. Kan YW, Dozy AM. Antenatal diagnosis of sickle-cell anaemia by DNA analysis of amniotic-fluid cells. 
Lancet 1978;312(8096):910-912. [http://dx.doi.org/10.1016/S0140-6736(78)91629-X]
7. Ramsay M, Thomson JA, Jenkins T. Antenatal diagnosis of sickle-cell anaemia by means of DNA 
restriction analysis. S Afr Med J 1984;66(1):7-10.
8. Ramsay M, Levin SL, Rosendorff J, et al. Chorionic villus sampling for first trimester diagnosis of betα-
thalassaemia. Report of the first South African case. S Afr Med J 1985;68(9):672-675.
9. Chong SS, Boehm CD, Higgs DR, et al. Single-tube multiplex-PCR screen for common deletional 
determinants of α-thalassaemia. Blood 2000;95(1):360-362. 
10. Krause A. Globin Genes of the South African Indian Population. PhD thesis. Johannesburg: University 
of the Witwatersrand, 1994.
11. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe 
complex mutations: A discussion. Human Mutat 2000;15(1):7-12 [http://dx.doi.org/10.1002/
(SICI)1098-1004(200001)15:1<7::AID-HUMU4>3.0.CO;2-N]
12. MRC-Holland. MLPA. http://www.mrc-holland.com/WebForms/WebFormMain.aspx (10 July 2013).
13. Park YJ. Recent Chinese migrations to South Africa: New intersections of race, class and ethnicity. In: 
Rahimy T, ed. Representation Expression and Identity: Interdisciplinary Perspectives. Oxford: Inter-
Disciplinary Press, 2009:153-168.
14. Nagel RL, Fleming AF. Genetic epidemiology of the βs globin gene. Baillière’s Clin Haematol 
1992;5(2):331-365.
15. Jenkins T. Genetic Polymorphisms of Man in Southern Africa. MD thesis. London: University of 
London, 1972.
16. Old JM. Hemoglobinopathies: Community Clues to Mutation Detection. In: Elles R, ed. Molecular 
Diagnosis of Genetic Diseases. New Jersey: Humana Press, 1996:169-183.
Accepted 22 August 2013. 
